Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

[D.ap]

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma


"The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.


PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes, according to a study presented at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois.1

Among adolescents and young adults with cancer, 10% to 15% have sarcoma, which carries a poor prognosis after metastasis or relapse.

For this retrospective analysis, researchers reviewed data from 14 adolescent and young adult patients with sarcoma to determine whether PD-1 inhibition is an effective strategy in this setting."



http://www.cancertherapyadvisor.com/sar ... le/670553/